Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells

Matayoshi,Sen; Chiba,Shunmei; Lin,Yanfui; Arakaki,Kazunari; Matsumoto,Hirofumi; Nakanishi,Takaya; Suzuki,Mikio; Kato,Seiya

doi:10.3892/ijo.2013.1849

Lysophosphatidic acid receptor 4 signaling potentially modulates malignant behavior in human head and neck squamous cell carcinoma cells

Authors:
- Sen Matayoshi
- Shunmei Chiba
- Yanfui Lin
- Kazunari Arakaki
- Hirofumi Matsumoto
- Takaya Nakanishi
- Mikio Suzuki
- Seiya Kato
View Affiliations

Affiliations: Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan, Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan
Published online on: March 5, 2013 https://doi.org/10.3892/ijo.2013.1849
Pages: 1560-1568
Copyright: © Matayoshi et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin cancer worldwide. Despite improvement in therapeutic strategies, the prognosis of advanced HNSCC remains poor. The extacellular lipid mediators known as lysophosphatidic acids (LPAs) have been implicated in tumorigenesis of HNSCC. LPAs activate G-protein-coupled receptors not only in the endothelial differentiation gene (Edg) family (LPA1, LPA2, LPA3) but also in the phylogenetically distant non-Edg family (LPA4, LPA5, LPA6). The distinct roles of these receptor isoforms in HNSCC tumorigenesis have not been clarified. In the present study, we investigated the effect of ectopic expression of LPA4 in SQ-20B, an HNSCC cell line, expressing a trivial level of endogenous LPA4. LPA (18:1) stimulated proliferation of SQ-20B cells, but did not affect proliferation of HEp-2, an SCC cell line expressing higher levels of LPA4, comparable to those of with LPA1. LPA-stimulated proliferation of SQ-20B cells was attenuated by Ki16425 and Rac1 inhibitor, but not by Y-27632. Infection with doxycycline-regulatable adenovirus vector expressing green fluorescent protein-tagged LPA4 (AdvLPA4G) abolished LPA-stimulated proliferation in SQ-20B cells with the accumulation of G2/M-phasic cells. Ectopic LPA4 induction further downregulated proliferation of Ki16425-treated SQ-20B cells, of which downregulation was partially recovered by LPA. Ectopic LPA4 induction also downregulated proliferation of Rac1 inhibitor-treated SQ-20B cells, however, LPA no longer recovered it. Finally, LPA-induced cell motility was suppressed by ectopic LPA4 expression as well as by Ki16425, Rac1 inhibitor or Y-27632. Our data suggest that LPA4 signaling potentially modulates malignant behavior of SQ-20B cells. LPA signaling, which is mediated by both Edg and non-Edg receptors, may be a determinant of malignant behavior of HNSCC and could therefore be a promising therapeutic target.

View Figures

View References

1.	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Argiris A, Karamouzis MV, Raben D and Ferris RL: Head and neck cancer. Lancet. 371:1695–1709. 2008. View Article : Google Scholar
3.	Matta A and Ralhan R: Overview of current and future biologically based targeted therapies in head and neck squamous cell carcinoma. Head Neck Oncol. 1:62009. View Article : Google Scholar : PubMed/NCBI
4.	Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, Shefler E, Ramos AH, Stojanov P, Carter SL, Voet D, Cortés ML, Auclair D, Berger MF, Saksena G, Guiducci C, Onofrio RC, Parkin M, Romkes M, Weissfeld JL, Seethala RR, Wang L, Rangel-Escareño C, Fernandez-Lopez JC, Hidalgo-Miranda A, Melendez-Zajgla J, Winckler W, Ardlie K, Gabriel SB, Meyerson M, Lander ES, Getz G, Golub TR, Garraway LA and Grandis JR: The mutational landscape of head and neck squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
5.	Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V and Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 45:324–334. 2009. View Article : Google Scholar : PubMed/NCBI
6.	Gendaszewska-Darmach E: Lysophosphatidic acids, cyclic phosphatidic acids and autotaxin as promising targets in therapies of cancer and other diseases. Acta Biochim Pol. 55:227–240. 2008.PubMed/NCBI
7.	Mills GB and Moolenaar WH: The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer. 3:582–591. 2003. View Article : Google Scholar : PubMed/NCBI
8.	Moolenaar WH: Lysophospholipids in the limelight: autotaxin takes center stage. J Cell Biol. 158:197–199. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, Yamori T, Mills GB, Inoue K, Aoki J and Arai H: Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol. 158:227–233. 2002. View Article : Google Scholar : PubMed/NCBI
10.	Tanaka M, Okudaira S, Kishi Y, Ohkawa R, Iseki S, Ota M, Noji S, Yatomi Y, Aoki J and Arai H: Autotaxin stabilizes blood vessels and is required for embryonic vasculature by producing lysophosphatidic acid. J Biol Chem. 281:25822–25830. 2006. View Article : Google Scholar
11.	Yanagida K and Ishii S: Non-Edg family LPA receptors: the cutting edge of LPA research. J Biochem. 150:223–232. 2011. View Article : Google Scholar : PubMed/NCBI
12.	Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN and Chun J: LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol. 50:157–186. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Meyer Zu Heringdorf D and Jakobs KH: Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim Biophys Acta. 1768:923–940. 2007.PubMed/NCBI
14.	Noguchi K, Ishii S and Shimizu T: Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. J Biol Chem. 278:25600–25606. 2003. View Article : Google Scholar : PubMed/NCBI
15.	Lee CW, Rivera R, Dubin AE and Chun J: LPA(4)/GPR23 is a lysophosphatidic acid (LPA) receptor utilizing G(s)-, G(q)/G(i)-mediated calcium signaling and G(12/13)-mediated Rho activation. J Biol Chem. 282:4310–4317. 2007. View Article : Google Scholar : PubMed/NCBI
16.	Yanagida K, Ishii S, Hamano F, Noguchi K and Shimizu T: LPA4/p2y9/GPR23 mediates rho-dependent morphological changes in a rat neuronal cell line. J Biol Chem. 282:5814–5824. 2007. View Article : Google Scholar : PubMed/NCBI
17.	Lee Z, Cheng CT, Zhang H, Subler MA, Wu J, Mukherjee A, Windle JJ, Chen CK and Fang X: Role of LPA4/p2y9/GPR23 in negative regulation of cell motility. Mol Biol Cell. 19:5435–5445. 2008. View Article : Google Scholar : PubMed/NCBI
18.	Liu YB, Kharode Y, Bodine PV, Yaworsky PJ, Robinson JA and Billiard J: LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4. J Cell Biochem. 109:794–800. 2010.PubMed/NCBI
19.	Gschwind A, Prenzel N and Ullrich A: Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res. 62:6329–6336. 2002.
20.	Suzuki Y, Ozawa Y, Murakami K and Miyazaki H: Lysophosphatidic acid inhibits epidermal-growth-factor-induced Stat1 signaling in human epidermoid carcinoma A431 cells. Biochem Biophys Res Commun. 240:856–861. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Rolin J and Maghazachi AA: Effects of lysophospholipids on tumor microenvironment. Cancer Microenviron. 4:393–403. 2011. View Article : Google Scholar : PubMed/NCBI
22.	Toyozumi Y, Arima N, Izumaru S, Kato S, Morimatsu M and Nakashima T: Loss of caspase-8 activation pathway is a possible mechanism for CDDP resistance in human laryngeal squamous cell carcinoma, HEp-2 cells. Int J Oncol. 25:721–728. 2004.PubMed/NCBI
23.	Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J and Ervin TJ: Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci USA. 83:2684–2688. 1986. View Article : Google Scholar : PubMed/NCBI
24.	Msaki A, Sánchez AM, Koh LF, Barré B, Rocha S, Perkins ND and Johnson RF: The role of RelA (p65) threonine 505 phosphor-ylation in the regulation of cell growth, survival and migration. Mol Biol Cell. 22:3032–3040. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M and Narumiya S: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 389:990–994. 1997. View Article : Google Scholar : PubMed/NCBI
26.	Lee CW, Rivera R, Gardell S, Dubin AE and Chun J: GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5. J Biol Chem. 281:23589–23597. 2006. View Article : Google Scholar : PubMed/NCBI
27.	Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, Tajima Y, Taguchi R, Shimizu T and Ishii S: Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem. 284:17731–17741. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Bhave SL, Teknos TN and Pan Q: Molecular parameters of head and neck cancer metastasis. Crit Rev Eukaryot Gene Expr. 21:143–153. 2011. View Article : Google Scholar
29.	Hall A: Rho GTPases and the control of cell behaviour. Biochem Soc Trans. 33:891–895. 2005. View Article : Google Scholar : PubMed/NCBI
30.	Routhier A, Astuccio M, Lahey D, Monfredo N, Johnson A, Callahan W, Partington A, Fellows K, Ouellette L, Zhidro S, Goodrow C, Smith A, Sullivan K, Simone P, Le L, Vezuli B, Zohni M, West E, Gleason D and Bryan B: Pharmacological inhibition of Rho-kinase signaling with Y-27632 blocks melanoma tumor growth. Oncol Rep. 23:861–867. 2010.PubMed/NCBI
31.	Moore KA, Sethi R, Doanes AM, Johnson TM, Pracyk JB, Kirby M, Irani K, Goldschmidt-Clermont PJ and Finkel T: Rac1 is required for cell proliferation and G2/M progression. Biochem J. 326:17–20. 1997.PubMed/NCBI
32.	Mack NA, Whalley HJ, Castillo-Lluva S and Malliri A: The diverse roles of Rac signaling in tumorigenesis. Cell Cycle. 10:1571–1581. 2011. View Article : Google Scholar : PubMed/NCBI
33.	Shoval I and Kalcheim C: Antagonistic activities of Rho and Rac GTPases underlie the transition from neural crest delamination to migration. Dev Dyn. 241:1155–1168. 2012. View Article : Google Scholar : PubMed/NCBI
34.	Guilluy C, Garcia-Mata R and Burridge K: Rho protein crosstalk: another social network? Trends Cell Biol. 21:718–726. 2011. View Article : Google Scholar : PubMed/NCBI
35.	Kramer RH, Shen X and Zhou H: Tumor cell invasion and survival in head and neck cancer. Cancer Metastasis Rev. 24:35–45. 2005. View Article : Google Scholar : PubMed/NCBI
36.	Abraham MT, Kuriakose MA, Sacks PG, Yee H, Chiriboga L, Bearer EL and Delacure MD: Motility-related proteins as markers for head and neck squamous cell cancer. Laryngoscope. 111:1285–1289. 2001. View Article : Google Scholar : PubMed/NCBI
37.	Abe M, Sogabe Y, Syuto T, Yokoyama Y and Ishikawa O: Evidence that PI3K, Rac, Rho and Rho kinase are involved in basic fibroblast growth factor-stimulated fibroblast-collagen matrix contraction. J Cell Biochem. 102:1290–1299. 2007. View Article : Google Scholar : PubMed/NCBI
38.	Harper K, Arsenault D, Boulay-Jean S, Lauzier A, Lucien F and Dubois CM: Autotaxin promotes cancer invasion via the lysophosphatidic acid receptor 4: participation of the cyclic AMP/EPAC/Rac1 signaling pathway in invadopodia formation. Cancer Res. 70:4634–4643. 2010. View Article : Google Scholar : PubMed/NCBI
39.	Zhang C, Baker DL, Yasuda S, Makarova N, Balazs L, Johnson LR, Marathe GK, McIntyre TM, Xu Y, Prestwich GD, Byun HS, Bittman R and Tigyi G: Lysophosphatidic acid induces neointima formation through PPARgamma activation. J Exp Med. 199:763–774. 2004. View Article : Google Scholar : PubMed/NCBI
40.	Liliom K, Tsukahara T, Tsukahara R, Zelman-Femiak M, Swiezewska and Tigyi G: Farnesyl phosphates are endogenous ligands of lysophosphatidic acid receptors: inhibition of LPA GPCR and activation of PPARs. Biochim Biophys Acta. 1761:1506–1514. 2006. View Article : Google Scholar : PubMed/NCBI
41.	Tsukahara T: The role of PPARγ in the transcriptional control by agonists and antagonists. PPAR Res. 2012:3623612012.
42.	Rodway HA, Hunt AN, Kohler JA, Postle AD and Lillycrop KA: Lysophosphatidic acid attenuates the cytotoxic effects and degree of peroxisome proliferator-activated receptor gamma activation induced by 15-deoxyDelta12,14-prostaglandin J2 in neuroblastoma cells. Biochem J. 382:83–91. 2004. View Article : Google Scholar